Resolutions from Sobi's Annual General Meeting

The Swedish Orphan Biovitrum AB (publ) (Sobi) Annual General Meeting (AGM) convened earlier today in Stockholm and voted in favour of the resolutions proposed at the meeting, including:

Adoption of the profit and loss statements and balance sheet and discharge of liability
The AGM adopted the income statements and the balance sheets and approved the proposal to carry forward the retained profits of SEK 4,561,601,316 .

The board members and the chief executive officer were discharged from liability for the financial year 2014.

Election of Board of Directors, remuneration to the Directors and election of Auditor
The ordinary board members Adine Grate Axén, Annette Clancy, Matthew Gantz, Bo Jesper Hansen, Lennart Johansson, Helena Saxon, Hans GCP Shikan and Hans Wigzell were re-elected and Bo Jesper Hansen was re-elected chairman of the Board.

The AGM approved the compensation to the Board in accordance with the nomination committee's proposal.

Ernst & Young was elected as auditor of Sobi until the end of the annual general meeting 2016.

Principles for remuneration for the management, long-term incentive program and transfer of own shares
The AGM approved the proposed guidelines for remuneration for the management.

The AGM also approved the Board's proposal regarding the implementation of a long-term incentive program, and hedging arrangements in respect of the program including a directed issue of no more than 1,036,856 series C shares, authorisation for the Board to decide on a repurchase of all issued series C shares and transfers of no more than 1,630,976 own common shares to program participants.

The Board's proposal regarding transfer of no more than 193,233 own common shares on the stock exchange for the purpose of covering certain payments, mainly social security contributions, that may occur in relation to the Share Program 2012, was also approved by the AGM.

For full details on each proposal adopted by the AGM please refer to www.sobi.com. 

- - -

About Sobi
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of specialty and rare disease products for partner companies across Europe, the Middle East, North Africa and Russia. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2014, Sobi had total revenues of SEK 2.6 billion (USD 380 M) and about 600 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

For more information please contact

The information was released for public distribution on June 30, 2015 at 16.15 p.m. CET.

025e_AGM resolutions http://hugin.info/134557/R/1933006/695647.pdf